AUROPHARMA

A Prescription for Explosive Growth

is currently exhibiting a powerhouse bullish structure as it enters May 2026, recently surging to a fresh 52-week high of 1,514.00, the stock is riding a sustained upward trajectory, holding firmly above all major moving averages, including the 50-day EMA (1,356.28) and 100-day EMA (1,291.34), which act as strong dynamic support levels. Fundamental strength backs this technical momentum, with a robust 8.4% YoY revenue growth in Q3 FY26 and a significant 27.4% surge in European formulation sales.